|View printer-friendly version|
|December 09, 2005 12:00 p.m.|
|Teva Announces Agreement with Cephalon Regarding Settlement of Provigil® Patent Litigation|
Parties Also Agree to Business Arrangements Related to Modafinil
Jerusalem, Israel, December 9, 2005 - Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) and Teva Pharmaceuticals USA, Inc. announced today that they have entered into an agreement with Cephalon, Inc. (Nasdaq: CEPH) to settle their pending patent infringement disputes in the United States and the United Kingdom related to PROVIGIL® (modafinil) Tablets [C-IV].